Bevacizumab provides a survival benefit in first- and second-line metastatic colorectal cancer (mCRC). In a large, observational, bevacizumab treatment study (Bevacizumab Regimens: Investigation of ...

Bevacizumab combined with fluorouracil-based chemotherapy has become the standard for first-line treatment of metastatic colorectal cancer. It may prove useful for other tumors as well.

Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despit ...

In patients with low-risk disease status, the addition of bevacizumab did not improve TTNT (21.4 vs 20.7 months) or OS (61.4 vs 63.2 months) versus chemotherapy alone. Disclosures BEV1L was ...

Early and intensive treatment of age-related macular degeneration with bevacizumab is associated with greater long-term improvements in visual acuity than are ranibizumab or aflibercept, a real ...

The discrepancy between stopping bevacizumab and stopping lomustine in the combination group was a result of treatment scheduling or toxic effects (15 of 144 patients [10.4%] in the monotherapy ...

Bevacizumab addition to chemotherapy showed significant progression-free survival benefits in high-risk epithelial ovarian cancer patients but not in overall survival. The BEV1L study used real ...

Several lines of evidence supported adding bevacizumab to platinum-containing chemotherapy. Vascular endothelial growth factor (VEGF)-A is the primary mediator of cancer growth and progression in ...

Patients were randomly assigned to receive capecitabine (2,500 mg/m 2 /d) twice daily on day 1 through 14 every 3 weeks, alone or in combination with bevacizumab (15 mg/kg) on day 1. The primary end ...

A real-world study published by Wiley online in CANCER and based on information from an electronic health records–derived database reveals limited benefits of adding bevacizumab to first-line ...